Navigation Links
Senetek PLC Investor Hotline Goes Live
Date:5/15/2009

Call 877-SENETEK or 707-259-6278

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced that an up-to-date audio recording of Company news and developments is now available by calling 877-SENETEK in the United States and Canada and 707-259-6278 from international locations.

"We are pleased to provide this service to our investors as a supplement to news releases, shareholder teleconferences and our quarterly and annual filings. Our mission is to keep the Senetek shareholder updated in a timely fashion," stated Frank J. Massino, Chairman and Chief Executive Officer of Senetek.

About Senetek PLC:

Senetek PLC (OTCBB: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites:

www.senetekplc.com

www.pyratine6.com

www.pyratinexr.com

or call: 877-SENETEK (United States and Canada) 707-259-6278 (International Locations)

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Announces New Investor Communication Hotline
2. Senetek PLC Announces 2008 Annual General Meeting Voting Results
3. Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
4. Senetek Affirms Strong Financial Position
5. Senetek PLC Reports Second Quarter 2008 Financial Results
6. Senetek PLC Reports First Quarter 2008 Financial Results
7. Senetek PLC Announces Appointments of Key Personnel
8. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
11. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... ... demand that it has found among its diverse customer base. The latest entry ... in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
Breaking Biology News(10 mins):